Abivax S.A. Stock
Price
Target price
€98.80
€98.80
-1.790%
-
-1.790%
-
09.01.26 / Tradegate
WKN: A14UQC / Name: Abivax / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Abivax S.A. Stock
A loss of -1.790% shows a downward development for Abivax S.A..
So far the community has only identified positive things for Abivax S.A. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Abivax S.A. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Cons
?
S********** s********
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Abivax S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Abivax S.A. | -1.790% | - | - | - | - | - | - |
| Transgene S.A. | 0.890% | -1.299% | 4.348% | 24.251% | -5.590% | -48.649% | -48.358% |
| Nanobiotix | 0.120% | -7.970% | -4.520% | 506.443% | -9.319% | 352.219% | 13.351% |
| Valneva SE | 1.610% | 11.047% | 11.047% | 96.587% | 12.990% | -35.228% | -43.550% |
Comments
DERFY stimmt der Outperform-Einschätzung der institutionellen Analysten zu
DERFY stimmt am 12.07.2016 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 26.97€ zu.News
EQS-News: Abivax to be Added to Nasdaq Biotechnology Index
EQS-News: Abivax to be Added to Nasdaq Biotechnology Index
EQS-News: Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
EQS-News: Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings